Vesalio's enVast Thrombectomy System NATURE Trial Selected as Late-Breaker at ESC Congress 2026
核心洞察
The randomized NATURE trial evaluating the enVast Coronary Thrombectomy System (搜索) will be presented as a Late-Breaking Clinical Trial at ESC Congress 2026 in Munich, Germany.
The prospective, multicenter study compares thrombectomy using enVast before conventional PCI versus standard of care alone in STEMI patients with large thrombus burden.
Marco Valgimigli, MD, will present results on Saturday, August 29, 2026, in a session focused on optimizing management of acute myocardial infarction.
The randomized NATURE clinical trial evaluating the enVast Coronary Thrombectomy System (搜索) has been selected for presentation as a Late-Breaking Clinical Trial at the European Society of Cardiology (ESC) Congress 2026, taking place August 28–31 in Munich, Germany. Vesalio (搜索), the device's manufacturer, announced the selection on July 21, 2026, marking a significant milestone for the company's cardiovascular portfolio.
The NATURE trial (ClinicalTrials.gov Identifier: NCT04969471) is a prospective, multicenter, randomized clinical trial designed to evaluate the safety and effectiveness of the enVast Coronary Thrombectomy System (搜索) as an adjunctive reperfusion strategy to conventional intervention in patients with ST-segment elevation myocardial infarction (搜索) (STEMI) and large thrombus burden undergoing primary percutaneous coronary intervention (PCI). The study compares thrombectomy using enVast before conventional PCI against standard of care alone.
"We are honored that the NATURE trial has been selected as a Late-Breaking Clinical Trial at ESC 2026," said Steve Rybka, Chief Executive Officer of Vesalio (搜索). "ESC is the world's largest cardiovascular congress, and this podium presentation is an important milestone for Vesalio and for the investigators who have contributed to this landmark study. We are excited to see the results of the randomized clinical data evaluating enVast presented to the global interventional cardiology community."
Presentation Details
The results will be delivered by Marco Valgimigli, MD, of the Cardiocentro Ticino Institute in Lugano, Switzerland, during the session titled "Late-Breaking Clinical Trials: Optimising Management of Acute Myocardial Infarction." The presentation is scheduled for Saturday, August 29, 2026, from 13:45 to 15:00 CEST in Hall A3 at ESC Congress 2026.
The session's focus on optimizing the management of acute myocardial infarction underscores the trial's scientific importance and the continued interest in advancing treatment options for patients with STEMI and large thrombus burden.
About the enVast Platform
The enVast Coronary Thrombectomy System (搜索) is part of Vesalio (搜索)'s proprietary portfolio, which also includes the NeVa and pVasc platforms. These devices are designed to effectively remove all types of clots and restore vital blood flow to compromised ischemic tissue in the brain, heart, and peripheral anatomy. According to the company, Vesalio's products have treated more than 19,000 patients in over 60 countries.
Vesalio (搜索) is a privately held medical device company focused on advancing patient care for thromboembolic vascular disease by providing physicians with technology aimed at improving clinical outcomes.